The “consensus” call is for the U.S. to experience a normal winter – but at least one “out-of-consensus” weather expert is calling for a much more severe winter with very heavy snow and very cold temperatures. When it comes to how to play a colder-than-expected winter, the author of today’s article “favor[s] natural gas plays over apparel and snow plows because they’re more disliked, and they face solid long-term catalysts beyond the cold winter surprise.” For these long-term catalysts and a number of U.S. natural gas plays the author finds particularly interesting, CLICK HERE.
While the Dow recently hit a record high, today’s article notes that “eleven Dow stocks, or more than a third of its components, are still in a correction or worse – those include Cisco, 3M, Pfizer, Exxon Mobil, Boeing and UnitedHealth among others” – and a pair of traders are highlighting one of those stocks as “the best way to play catch-up” to the Dow’s rally. For this stock – as well as a different Dow “catch-up” play preferred by another trader – CLICK HERE.
What stocks are the most loved on Wall Street right now? Today’s article identifies the S&P 500 companies whose stocks currently have the highest percentage of Buy ratings – and the #1 most loved stock on Wall Street right now by this measure is Amazon, with 47 out of 48 analysts covering the stock rating it a Buy. What stocks join the e-commerce giant on the “most-loved” list? CLICK HERE.
When stocks fell in the final months of last year, water stocks bucked the trend – and water stocks have crushed the S&P 500 over the last six months. As the author of today’s article explains, “Stock market volatility is part of the reason water stocks are doing so well right now…When stock market risk rises, investors flock to safe and reliable stocks. And water stocks fit that bill.” For more on how water stocks can “buoy your portfolio” – including what the author highlights as the best ways to invest in water right now – CLICK HERE.
A boom in the building of super-tall residential and commercial towers is underway – and it may signal the end of the bull market. At least that’s the thinking underlying the so-called “skyscraper indicator”, which today’s article explains is based on the fact that “In the past, the completion of record-high skyscrapers has been the proverbial bell that rings at the top of the market” as the same “peak hubris” infecting investors also infects real-estate developers. For more, CLICK HERE.
Halloween is over and assorted monster costumes have been put away – but there is still monster growth to be had in certain stocks! Today’s article highlights three stocks “with strong monster growth narratives” – each of which has recently reported impressive earnings numbers and had their price targets increased by some of Wall Street’s top-performing analysts as a result. For these three “monster growth” stocks – all of which have “Strong Buy” consensus ratings and upside potential above 20% – CLICK HERE.
Is a year-end rally – or so-called “Santa Claus Rally” – already underway in the stock market? As today’s article notes, among those who subscribe to the notion of a Santa Claus Rally, some believe it begins in late October. Based on the historical record, however, the author questions whether the Santa Claus Rally really even exists, declaring that, “The stock market will rally between now and the end of the year. But that doesn’t mean there will be the ‘year-end rally’ that many advisers have begun telling their clients to expect.” For more, CLICK HERE.
Each member of the popular and closely-watched FAANG stocks, as well as Microsoft, reported their most recent quarterly earnings in October – and the gains that followed some solid earnings figures helped propel the S&P 500 to an all-time high. For how each of the FAANG stocks (and Microsoft) performed in quarterly earnings, as well as how much each stock has gained so far this year, CLICK HERE.
With approximately 100 new biotech companies having begun trading on the Nasdaq exchange since the beginning of last year alone, the author of today’s article observes that “There are so many new biotech stocks hitting the market that plenty of gems slip through the cracks unnoticed” – and he goes on to highlight two of them. For these two under-the-radar biotechs – one of which has developed a potential new treatment for depression while the other “is taking advantage of gravity to develop a blindness prevention drug that lasts longer than the competition” – CLICK HERE.
Benchmark indexes are close to all-time highs and, with no lack of economic, political and geopolitical risks, market sentiment is hardly exuberant – so why does the author of today’s article suggest that “The U.S. stock market is likely to rise to all-time highs soon and potentially extend gains even further”? For a bullish, contrarian analysis of the current market situation, CLICK HERE.